[HTML][HTML] Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study
BH Kushner, K Kramer, S Modak… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
BH Kushner, K Kramer, S Modak, NKV Cheung
Journal of Clinical Oncology, 2011•ncbi.nlm.nih.govPurpose Pain can hinder immunotherapy with anti-G D2 monoclonal antibodies (MoAbs)
like 3F8. Heat-modified 3F8 (HM3F8) lacks effector functions and could mask G D2 or cross-
reactive epitopes on nerves, thereby preventing a subsequent dose of unmodified 3F8 from
activating pain fibers. We hypothesized that 3F8 dose escalation is possible without
increased analgesic requirements in patients pretreated with HM3F8.
like 3F8. Heat-modified 3F8 (HM3F8) lacks effector functions and could mask G D2 or cross-
reactive epitopes on nerves, thereby preventing a subsequent dose of unmodified 3F8 from
activating pain fibers. We hypothesized that 3F8 dose escalation is possible without
increased analgesic requirements in patients pretreated with HM3F8.
Abstract
Purpose
Pain can hinder immunotherapy with anti-G D2 monoclonal antibodies (MoAbs) like 3F8. Heat-modified 3F8 (HM3F8) lacks effector functions and could mask G D2 or cross-reactive epitopes on nerves, thereby preventing a subsequent dose of unmodified 3F8 from activating pain fibers. We hypothesized that 3F8 dose escalation is possible without increased analgesic requirements in patients pretreated with HM3F8.
ncbi.nlm.nih.gov